INSM Insmed (INSM) Q2 FY26 earnings call
Insmed delivered an exceptionally strong quarter, driven by the continued historic launch trajectory of BRINSUPRI, which saw significant revenue and new patient growth, leading to a substantial increase in full-year guidance. The company also raised peak sales estimates for BRINSUPRI and TPIP, reflecting increased confidence in their market potential and clinical differentiation. Insmed remains financially strong, reiterating its path to cash flow positivity in 2027 without additional capital raises, while continuing to invest in pipeline expansion and commercial infrastructure.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
INSM operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Patients BRINSUPRI New Starts | ~7,800Similarly, in Q1, we estimate that about 1,500 of the roughly 7,800 new patients who started treatment in the quarter were part of this ready and waiting patient group.Source: earnings call transcript | ~7,000BRINSUPRI added approximately 7,000 new patients in the second quarter, exceeding our previous expectation of approximately 6,300 new patient starts.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.